Freedom Broker raises Abbvie stock price target on strong results
Freedom Broker raised its price target on AbbVie (NYSE:ABBV) to $315 from $285, citing strong quarterly results and raised guidance. The company's revenue grew 10.68% over the last twelve months, with shares trading near their 52-week high. Several other analysts also increased their price targets following AbbVie's strong third-quarter performance, which exceeded estimates.
How this was made
The 30-second read
Why it matters
While the price target increase signals optimism, the news largely repeats already‑public earnings data.
Market read
Limited trading relevance; mainly an analyst opinion after earnings.
What to watch
Potential competition for Rinvoq and Skyrizi not fully addressed.
Background
The article recaps analyst price target upgrades following AbbVie's recent earnings beat.
Ticker impact
Freedom Broker raised its price target on AbbVie to $315, citing strong quarterly results and guidance upgrades.
likely upward pressure as investors price in the higher target.
The new target reflects better earnings and pipeline progress, which may attract buying.
Market effects
Positive sentiment may lift broader pharma sector.
U.S. market focus, limited regional effect.
Modest, confined to AbbVie and peers.
Counterpoint
The price target raise may be premature if pipeline risks materialize.
Key entities
- companyAbbVie
U.S. pharmaceutical company (ticker ABBV).
- analyst_firmFreedom Broker
Equity research firm that raised the price target.
